This non-interventional, observational study evaluates the efficacy of Targinact with regard to quality of life in daily clinical practice in Belgium compared to the previous analgesic treatment.
Patients are treated with Targinact® according to daily clinical practice during at least 12 weeks and are monitored during study 3 visits. Parameters assessed are overall health assessment of the patient, pain relief, constipation, use of laxatives, use of analgesic rescue medication, use of concomitant medication, quality of life and safety of Targinact® treatment. These parameters, except for safety assessment, are compared between Targinact® treatment and previous analgesic treatment.
Study Type
OBSERVATIONAL
Enrollment
1,800
University Hospital Brussels (UZ Brussel), Belgium
Brussels, Belgium
RECRUITINGAssess the efficacy of Targinact® treatment
The primary parameter to assess the efficacy of Targinact® treatment with respect to the quality of life (overall health assessment/EQ-VAS) in patients with chronic severe pain compared to previous analgesic treatment is the absolute change in overall health score (0-100) attributed by patients during Targinact® treatment compared to previous analgesic treatment. During each visit, patients will be asked to score their overall health state between 0 (worst health state imaginable) and 100 (best health state imaginable). The absolute changes in overall health assessment from baseline at V2 and V3 will be used to compare health assessment during Targinact® treatment.
Time frame: 12 weeks
• To assess pain (NRS) during Targinact® treatment compared to previous analgesic treatment (by physician)
To assess pain (NRS) during Targinact® treatment compared to previous analgesic treatment (by physician)
Time frame: 12 weeks
To assess constipation (BFI) during Targinact® treatment compared to previous analgesic treatment (by physician)
To assess constipation (BFI) during Targinact® treatment compared to previous analgesic treatment (by physician)
Time frame: 12 weeks
To assess laxative use during Targinact® treatment compared to previous analgesic treatment (by physician)
To assess laxative use during Targinact® treatment compared to previous analgesic treatment (by physician)
Time frame: 12 weeks
To assess the use of analgesic rescue medication during Targinact® treatment compared to previous analgesic treatment (by physician)
To assess the use of analgesic rescue medication during Targinact® treatment compared to previous analgesic treatment (by physician)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 12 weeks
To evaluate the quality of life (EQ-5D questionnaire) during Targinact® treatment compared to previous analgesic treatment (by patient)
To evaluate the quality of life (EQ-5D questionnaire) during Targinact® treatment compared to previous analgesic treatment (by patient)
Time frame: 12 weeks
To assess safety of Targinact® treatment (by physician)
Safety will be assessed by documentation of adverse events, collected via spontaneous reports and patient documentation.
Time frame: 12 weeks